Leap Therapeutics Inc (NAS:LPTX)
$ 2.38 -0.09 (-3.64%) Market Cap: 91.07 Mil Enterprise Value: 40.18 Mil PE Ratio: 0 PB Ratio: 1.29 GF Score: 46/100

Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 21, 2021 / 05:20PM GMT
Release Date Price: $17 (-2.30%)
Timur Ivannikov
Raymond James & Associates, Inc. - Analyst

Hello, everybody. So my name is Timur Ivannikov, and I am an analyst -- biotech analyst at Raymond James. Today, we are pleased to host Leap Therapeutics at our annual Human Health Innovation Conference.

So joining us for a fireside chat today is Leap Therapeutics' President and CEO, Doug Onsi; and CMO, Cyndi Sirard. Thank you very much, Doug and Cyndi, for joining us, and thanks to everyone as well.

So -- and to start off, Doug, maybe you could provide a brief overview of Leap Therapeutics, given we are approaching an important data catalyst in 3Q 2021 in gastroesophageal cancer.

Doug Onsi
Leap Therapeutics, Inc. - President & CEO

Good afternoon, Timur. Thank you very much to you and Raymond James for inviting us to participate in the conference.

Leap Therapeutics is an oncology drug development company focused on developing our DKN-01 monoclonal antibody. And DKN-01 targets DKK1, which is a protein produced by cancer cells that modulates important cell signaling

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot